Journal ArticleDOI
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
Paul G. Richardson,Sundar Jagannath,Ajai Chari,Dan T. Vogl,Meletios A. Dimopoulos,Philippe Moreau,David Dingli,L. J. Wei,Lingling Li,Shijie Tang,William Reichman,Michael Kauffman,Jatin J. Shah,Sharon Shacham,Sagar Lonial +14 more
TLDR
TCR-MM is defined as being refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 mAbs, representing an urgent unmet medical need with a median OS of 3-5 months.Abstract:
8014Background: TCR-MM is defined as being refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 mAbs, representing an urgent unmet medical need with a median OS of 3-5 months...read more
Citations
More filters
Journal ArticleDOI
Selinexor: First Global Approval.
TL;DR: The milestones in the development of selinexor leading to this first approval for RRMM are summarized.
Journal ArticleDOI
Selinexor for the treatment of multiple myeloma.
TL;DR: Selinexor represents a next-generation-novel agent with an innovative mechanism of action that marks a significant advance in the treatment of heavily pretreated MM patients, and ongoing studies investigate its therapeutic potential also in earlier lines of therapy.
Journal ArticleDOI
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath,Yi Lin,Hartmut Goldschmidt,Donna E. Reece,Ajay K. Nooka,Alicia Senin,Paula Rodriguez-Otero,Ray Powles,Kosei Matsue,Nina Shah,Larry D. Anderson,Matthew Streetly,Kimberly Wilson,Hoa Van Le,Arlene S. Swern,Amit Agarwal,David S. Siegel +16 more
TL;DR: In this article, triple-class exposed multiple myeloma (RRMM) patients were treated with ideabtagene vicleucel (ide-cel, bb2121) and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting.
Journal ArticleDOI
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Robert F. Cornell,Parameswaran Hari,Shijie Tang,Noa Biran,Natalie S. Callander,Ajai Chari,Saurabh Chhabra,Mark A. Fiala,Zhubin Gahvari,Ujjawal H. Gandhi,Kelly N. Godby,Ridhi Gupta,Sundar Jagannath,Megan Jagosky,Yubin Kang,Ankit Kansagra,Michael Kauffman,Saranya Kodali,Shaji Kumar,Arjun Lakshman,Michaela Liedtke,Sagar Lonial,Xiwen Ma,Ehsan Malek,Joshua Mansour,Joshua Mansour,Elizabeth McGehee,Amarendra K. Neppalli,Barry Paul,Paul G. Richardson,Emma C. Scott,Sharon Shacham,Jatin P. Shah,David S. Siegel,Elvira Umyarova,Saad Z. Usmani,William Varnado,Ravi Vij,Luciano J. Costa +38 more
TL;DR: A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania and the World Health Organization and Health Action International's Measuring Medicine Price, Availability, Affordability and Price Component.
Journal ArticleDOI
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
TL;DR: Selinexor represents a novel, oral agent with an innovative mechanism of action that offers a significant therapeutic advance in this group of heavily treated patients and may provide additional options for patients with less refractory disease.
Related Papers (5)
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
Ajai Chari,Dan T Vogl,Maria Gavriatopoulou,Ajay K. Nooka,Andrew Yee,Carol Ann Huff,Philippe Moreau,David Dingli,Craig E. Cole,S. Lonial,Meletios A. Dimopoulos,A. Keith Stewart,Joshua Richter,Ravi Vij,Sascha Tuchman,Marc S Raab,Katja Weisel,Michel Delforge,Robert F Cornell,David Kaminetzky,James E. Hoffman,Luciano J. Costa,Terri L. Parker,Moshe Yair Levy,Martin Schreder,Nathalie Meuleman,Laurent Frenzel,Mohamad Mohty,Sylvain Choquet,Gary J. Schiller,Raymond L Comenzo,Monika Engelhardt,Thomas Illmer,Philip Vlummens,Chantal Doyen,Thierry Facon,Lionel Karlin,Aurore Perrot,Klaus Podar,Michael Kauffman,Sharon Shacham,Lingling Li,Shijie Tang,Carla Picklesimer,Jean-Richard Saint-Martin,Marsha Crochiere,Hua Chang,Samir Parekh,Yosef Landesman,Jatin Shah,Paul G. Richardson,Sundar Jagannath +51 more
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H. Gandhi,Robert F. Cornell,Arjun Lakshman,Zhubin Gahvari,Elizabeth McGehee,Megan Jagosky,Ridhi Gupta,William Varnado,Mark A. Fiala,Saurabh Chhabra,Ehsan Malek,Joshua Mansour,Barry Paul,Alyssa Barnstead,Saranya Kodali,Amarendra K. Neppalli,Michaela Liedtke,Swapna Narayana,Kelly N. Godby,Yubin Kang,Ankit Kansagra,Elvira Umyarova,Emma C. Scott,Parameswaran Hari,Ravi Vij,Saad Z. Usmani,Natalie S. Callander,Shaji Kumar,Luciano J. Costa +28 more